IRON TRIANGLE PARTNERS LP
Q1 2023 Form 13-F

COS COB, CONNECTICUT
CIK 0001779763 · CRD 302077 · SEC-registered investment adviser
$693.2M Reported Value Total

IRON TRIANGLE PARTNERS LP reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $1,141,018,483, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $359.6M gross asset value
Hedge Fund: $359.6M
Source: Form ADV filed 2026-03-24
Reported value
$693.2M
Quarter over quarter
+6.2%
Holdings
27
Top-10 concentration
57.7%

Key People

Form ADV owners & control persons
Kevin Thomas Molloy
LIMITED PARTNER
Michael John O'Brien
CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2023 13F record

Q1 2023 13F filing summary

Q1 2023 Form 13F portfolio summary
Period of report March 31, 2023
Filed May 15, 2023
Form 13F-HR
Reported value $693.2M
Positions 27
Change in reported value +24.3%
New positions 12
Exited positions 11
Position turnover 60.5%
Top-10 concentration 57.7%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q4 2025 13F
Filed Feb 17, 2026
27 $874.7M
Q3 2025 13F
Filed Nov 14, 2025
25 $703.3M
Q2 2025 13F
Filed Aug 14, 2025
26 $651.2M
Q1 2025 13F
Filed May 15, 2025
27 $634.4M
Q4 2024 13F
Filed Feb 14, 2025
22 $908.4M
Q3 2024 13F
Filed Nov 14, 2024
24 $721.8M
Q2 2024 13F
Filed Aug 14, 2024
24 $983.7M
Q1 2024 13F
Filed May 15, 2024
28 $976.3M
Q4 2023 13F
Filed Feb 14, 2024
26 $772.9M
Q3 2023 13F
Filed Nov 14, 2023
23 $684.2M
Q2 2023 13F
Filed Aug 14, 2023
22 $748.1M
Q1 2023 13F
Filed May 15, 2023
27 $693.2M
Q4 2022 13F
Filed Feb 14, 2023
26 $557.8M
Q3 2022 13F
Filed Nov 14, 2022
27 $572.0M
Q2 2022 13F
Filed Aug 15, 2022
24 $771.2M
Q1 2022 13F
Filed May 16, 2022
28 $840.7M
Q4 2021 13F
Filed Feb 14, 2022
25 $717.7M
Q3 2021 13F
Filed Nov 15, 2021
26 $696.8M
Q2 2021 13F
Filed Aug 16, 2021
26 $970.8M
Q1 2021 13F
Filed May 17, 2021
27 $786.5M

5 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2023

Largest Q1 2023 13F positions by reported value
# Holding Reported value % of portfolio
1 SNY SANOFI $64.2M 9.26%
2 ABBV ABBVIE INC $51.0M 7.36%
3 ICLR ICON PLC $40.6M 5.85%
4 DXCM DEXCOM INC $39.5M 5.7%
5 UNH UNITEDHEALTH GROUP INC $37.8M 5.45%
6 ACHC ACADIA HEALTHCARE COMPANY IN $37.0M 5.34%
7 GILD GILEAD SCIENCES INC $34.8M 5.03%
8 EVH EVOLENT HEALTH INC $32.5M 4.68%
9 COO COOPER COS INC $31.7M 4.58%
10 ISRG INTUITIVE SURGICAL INC $30.7M 4.42%
11 ESTA ESTABLISHMENT LABS HLDGS INC $28.8M 4.15%
12 SGRY SURGERY PARTNERS INC $28.1M 4.06%
13 PACB PACIFIC BIOSCIENCES CALIF IN $26.6M 3.84%
14 CRL CHARLES RIV LABS INTL INC $26.2M 3.78%
15 IDXX IDEXX LABS INC $25.0M 3.61%
16 LEGN LEGEND BIOTECH CORP $24.1M 3.48%
17 SRPT SAREPTA THERAPEUTICS INC $22.1M 3.18%
18 TXG 10X GENOMICS INC $19.5M 2.82%
19 INSP INSPIRE MED SYS INC $16.4M 2.36%
20 SDGR SCHRODINGER INC $15.7M 2.26%

Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings